12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Simeprevir: Phase III data

The double-blind, international Phase III PROMISE trial in 393 patients with HCV genotype 1 infection who relapsed after previous interferon-based therapy showed that a significantly greater proportion of patients who received once-daily 150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a and Copegus ribavirin for 24 or 48 weeks (n=260) met the primary endpoint of a greater proportion of patients achieving...

Read the full 313 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >